COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION

被引：0
|
作者：
Castro-gomez, A. J. [1 ]
Lopez-Guillermo, A. [2 ]
Rueda, A. [3 ]
Salar, A. [4 ]
Rubio-Terres, C. [5 ]
机构：
[1] Roche Farma SA, Madrid, Spain
[2] Hosp Clin Barcelona, Barcelona, Spain
[3] Hosp Costa del Sol, Marbella, Andalucia, Spain
[4] Hosp del Mar, Barcelona, Spain
[5] HealthValue, Madrid, Spain
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.1170
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A446 / A446
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF MAINTENANCE TREATMENT WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA RESPONDING TO FIRST LINE INDUCTION THERAPY IN PORTUGAL
    Pereira, C.
    Rubio Terres, C.
    Rubio Rodriguez, D.
    VALUE IN HEALTH, 2014, 17 (07) : A530 - A531
  • [2] Cost-Effectiveness Analysis of Maintenance Therapy with Rituximab in Patients with Follicular Lymphoma Responding to Induction Therapy at the First Line
    Castro Gomez, Antonio J.
    Lopez-Guillermo, Armando
    Rueda Dominguez, Antonio
    Salar, Antonio
    Varela Moreno, Cristina
    Rubio-Terres, Carlos
    REVISTA ESPANOLA DE SALUD PUBLICA, 2012, 86 (02): : 163 - 176
  • [3] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Sabater, Eliazar
    Lopez-Guillermo, Armando
    Rueda, Antonio
    Salar, Antonio
    Oyaguez, Itziar
    Manuel Collar, Juan
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (04) : 465 - 477
  • [4] Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain
    Eliazar Sabater
    Armando López-Guillermo
    Antonio Rueda
    Antonio Salar
    Itziar Oyagüez
    Juan Manuel Collar
    Applied Health Economics and Health Policy, 2016, 14 : 465 - 477
  • [5] Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy
    Hornberger, John
    Chien, Rebecca
    Friedmann, Mark
    Han, Leona
    Shewade, Ashwini
    Satram-Hoang, Sacha
    Reyes, Carolina
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2371 - 2377
  • [6] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
    Sabater, E.
    Rueda, A.
    Salar, A.
    Lopez-Guillermo, A.
    Oyagueez, I.
    Collar, J. M.
    HAEMATOLOGICA, 2014, 99 : 487 - 488
  • [7] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
  • [8] Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Folio First-Line Therapy in Patients with Follicular Lymphoma
    Chen, Qiushi
    Ayer, Turgay
    Nastoupil, Loretta J.
    Rose, Adam C.
    Flowers, Christopher R.
    VALUE IN HEALTH, 2015, 18 (02) : 189 - 197
  • [9] Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
    Kasteng, Frida
    Erlanson, Martin
    Hagberg, Hans
    Kimby, Eva
    Relander, Thomas
    Lundkvist, Jonas
    ACTA ONCOLOGICA, 2008, 47 (06) : 1029 - 1036
  • [10] COST-EFFECTIVENESS OF RITUXIMAB IN FOLLICULAR LYMPHOMA FIRST LINE MAINTENANCE TREATMENT FROM PUBLIC PAYER PERSPECTIVE IN POLAND
    Gadaj, A.
    Kalinowska, A.
    Hawrylecka, D.
    Holojda, J.
    Krawcewicz, A.
    Spychalowicz, W.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A450
12345